Immunochemistry Analyzer Suitable for Low- to Mid-Volume Labs

A new immunochemistry analyzer has been introduced, which was designed for labs that typically perform less than 200 immunoassay tests per day. The instrument addresses many of the workflow challenges common in today's laboratories.

Called the Architect i1000SR analyzer, the new instrument enhances workflow and boosts laboratory productivity. Developed by Abbott (Abbott Park, IL, USA), the analyzer expands the Architect family of diagnostics instrument systems for clinical laboratories. The Architect i1000SR provides continuous access to reagents and samples while the instrument is running, enhancing laboratory productivity. Additionally, a wide test menu, user-friendly software, and low maintenance make it easy to train new laboratory personnel on the instrument's operation.

The Architect i1000SR analyzer can process up to 100 tests per hour. The instrument accommodates 65 patient samples and has the capability to prioritize emergency test results and turn them around in less than 16 minutes.

"Because time and ease of use are so critical in the testing environment, Abbott worked extensively with customers very early in the development phase and designed an instrument that could help smaller labs overcome the same productivity obstacles faced by larger labs,” said Cass Grandone, divisional vice president, Systems Development, Abbott Diagnostics. "The Architect i1000SR analyzer is ideal for facilities running less than 200 tests per day and offers productivity benefits, such as highly efficient sample processing, usually reserved for larger testing facilities. Since Architect utilizes common reagents, consumables, and software user interfaces, larger laboratories may be interested in using the instrument as a back-up system to the i2000SR.”

Similar to Architect ci8200 and ci16200, the analyzer is part of the Architect family, with important features including: family commonality, enhanced assay and system dynamics, and integration of immunoassay and clinical chemistry technologies without jeopardizing key performance, including turnaround time or accuracy of results.


Related Links:
Abbott